Novartis' approved sickle cell disease drug fails to beat placebo in PhIII

Novartis' approved sickle cell disease drug fails to beat placebo in PhIII

Source: 
Endpoints
snippet: 

Novartis’ sickle cell drug, approved in 2019 and branded as Adakveo, has failed an ongoing Phase III, according to preliminary results.